JNJ Company Profile and Key Details

Q: Who are the executives of JNJ?

Mr. Robert J. Decker Jr.Controller & Chief Accounting OfficerDr. Peter M. Fasolo Ph.D.Executive Vice President & Chief HR OfficerMs. Elizabeth ForminardExecutive Vice President & Gen. CounselMr. Alex GorskyExecutive ChairmanDr. Guy J. Lebeau M.D.Group Chairman of MD&D Bus. - EMEAMr. Joseph J. Wolk C.P.A.Executive Vice President & Chief Financial OfficerMs. Ashley A. McEvoyExecutive Vice President & Worldwide Chairman of MedTechMr. Thibaut MongonChief Executive Officer & DirectorMs. Jennifer L. TaubertExecutive Vice President & Worldwide Chairman of PharmaceuticalsDr. John C. Reed M.D., Ph.D.Executive Vice President of Pharmaceuticals R&DMr. Joseph J. Wolk CPAExecutive Vice President & Chief Financial OfficerMr. Dirk BrinckmanChief Compliance OfficerMr. Joaquin DuatoChief Executive Officer & DirectorMr. James SwansonExecutive Vice President & Chief Information OfficerMs. Jessica MooreVice President of Investor Relations

NYSE : JNJ

Johnson & Johnson

$243.04

-1.08-0.44%

At Close 4:00 PM

73.93

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Johnson & Johnson (JNJ) stock declined over -0.44%, trading at $243.04 on NYSE, down from the previous close of $244.12. The stock opened at $245.11, fluctuating between $242.00 and $247.21 in the recent session.

Stock Snapshot

244.12

Prev. Close

585.7B

Market Cap

241.995

Day Low

22.03

P/E Ratio

11.03

EPS (TTM)

6.52

Cash Flow per Share

245.11

Open

2.41B

Number of Shares

247.21

Day High

99.84%

Free Float in %

28.3

Book Value

5.28M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	245.11	247.21	241.87	243.04	6.61M
Apr 01, 2026	245.60	247.20	243.74	244.12	6.31M
Mar 31, 2026	243.01	245.33	242.65	244.44	7.55M
Mar 30, 2026	243.49	244.21	240.51	242.49	7.22M
Mar 27, 2026	241.19	242.68	239.13	240.45	7.55M
Mar 25, 2026	236.80	241.46	235.73	239.93	6.45M
Mar 24, 2026	234.14	236.00	232.24	235.27	8.82M
Mar 23, 2026	237.40	238.31	234.25	235.42	7.3M
Mar 20, 2026	236.83	238.29	234.50	235.37	17.07M
Mar 19, 2026	238.34	239.26	236.31	237.60	7.48M
Mar 18, 2026	237.87	239.11	235.42	237.28	6.67M
Mar 17, 2026	243.58	244.14	237.22	238.11	7.1M
Mar 16, 2026	243.92	245.06	241.67	243.19	7.56M
Mar 13, 2026	244.21	245.59	241.50	241.52	6.41M
Mar 12, 2026	241.46	244.40	240.30	242.04	7.7M
Mar 11, 2026	242.87	243.69	241.36	242.99	6.93M
Mar 10, 2026	242.30	245.00	240.82	243.71	7.21M
Mar 09, 2026	240.87	244.09	240.04	242.59	7.82M
Mar 06, 2026	238.12	240.79	235.43	240.40	7M
Mar 03, 2026	246.46	247.88	244.36	246.75	5.75M

Contact Details

New Brunswick, NJ 08933

United States

https://www.jnj.com 732 524 0400

About Company

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Stock Peers

LLY

-18.9-1.98%

Eli Lilly and Company$935.62 ABBV

-6.185-2.88%

AbbVie Inc.$208.80 AZN

2.76+1.37%

AstraZeneca PLC$203.49 NVS

-1.05-0.68%

Novartis AG$154.03 MRK

0.03+0.02%

Merck & Co., Inc.$120.87 BMY

-2.13-3.45%

Bristol-Myers Squibb Company$59.60 GSK

0.7+1.25%

GSK plc$56.69 NVO

0.495+1.36%

Novo Nordisk A/S$36.98 PFE

-0.22-0.77%

Pfizer Inc.$28.33 OGN

0.22+3.58%

Organon & Co.$6.36

Company Overview

Johnson & Johnson (NYSE:JNJ) closed at $243.04 USD, losing -$1.08 (-0.44%) from the previous close of $244.12. The stock is currently within 5% of its 52-week high $141.50 and $251.71. With a market capitalization of about $585.70 billion, Johnson & Johnson is classified as a mega-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 8.87 million shares, volume is running light vs its 52-week average. Headquartered in New Brunswick, NJ, Johnson & Johnson operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Joaquin Duato, the company employs approximately 138,100 people and listed since January 02, 1943. Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue.

Technical Performance

JNJ has shown sold momentum, gaining 4.05% over the past week and 12.93% over the past quarter, though year-to-date performance is up 5.44%. Short-term trend indicators are bearishly aligned (SMA20 1.56%, SMA50 9.13%, SMA200 29.93%). The stock’s 14-day RSI is 66.51 (firm momentum), while the ATR of 3.71 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.52% below its high and over 72.08% above its low. Average 10-day trading volume of 6.95 million shares is below the 3-month average of 8.80 million, indicating normal recent market interest.

Valuation Metrics

Johnson & Johnson trades at a P/E ratio of 22.02, slightly below the S&P 500 average, with a price-to-sales ratio of 6.22 and a price-to-book ratio of 7.24 trading at moderately above to book value. The P/FCF stands at 29.73, also below market averages.

Dividend & Fair Value

Johnson & Johnson last paid a dividend of 5.2 per share, this equals a trailing yield of roughly 3.09%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $280.66. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Johnson & Johnson generated EPS of $11.05 over the past year. Five-year average earnings growth is 14.9%. Wall Street analysts project EPS growth of 8.28% annually over the next five years. The latest quarter delivered EPS of $2.80. The next quarter is forecast at $2.69. Next year's EPS is expected at $7.19. Analyst sentiment is neutral. Analyst rating data shows there are 10 Strong Buy ratings, 16 Buy ratings, 26 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $280.00 to $159.00. The high target offers 15.21% upside. The low target suggests -34.58% downside. The mean target is $211.67. This offers -12.91% upside. Johnson & Johnson earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 14, 2025, missed forecasts by 1.45%. The prior quarter beat by 3.36%. Over the last six quarters, Apple has recorded several small beats. These include 4.06% in July 17, 2024.

Shareholding & Insider Activity

Johnson & Johnson has 2.41 billion shares outstanding. The public float is 2.40 billion shares, elevated short interest at 0.71% of float. This equals 17.14 million shares. The short ratio is 2.0 days. Institutional investors hold 74.41% of the float. Insiders own 0.06%. Taubert Jennifer L holds 178.01 thousand shares, Fasolo Peter has 102.70 thousand shares and Hait William has 87.75 thousand shares. Over the past six months, insider transactions show net selling. They sold 161.05 thousand shares across 10 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Johnson & Johnson generated $85.15B in revenue, or $33.26 per share. Gross margin was 68.60%, operating margin 25.66%, and net profit margin 41.28%. Returns are exceptional, with ROA at 20.98% and ROE at 51.11%.
On valuation metrics, Johnson & Johnson trades at a P/E of 22.02, P/S of 6.22 and P/B of 7.24. The current ratio is 1.03 and quick ratio is 0.77. Operationally, the company’s inventory turnover is 1.81 and cash conversion cycle is 97.89 days. Debt-to-equity is 0.59, supported by a cash flow-to-debt ratio of 0.51.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Johnson & Johnson posted revenue of $85.15B, down slightly from $94.94B in the prior quarter. Gross profit was $58.41B (margin 68.60%). Operating income was $21.85B (margin 25.7%). Net income was$35.15B (EPS $14.60).
The company ended the quarter with $22.93B in cash and short-term investments, a total debt of $30.43B, and net debt of $8.57B. Total assets were $167.56B, with equity of $68.77B. Financials further reflected stability, with operating cash flow of $22.79B, free cash flow of $18.25B, and capital expenditures of - $4.54B.

Price Forecast & Outlook

Our AI price prediction model suggests that Johnson & Johnson stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.63%, with price expected at $256.72 by April 16, 2026, within a range of $252.61 to $261.26 3-Month Outlook: Projected rise of 25.38%, reaching $304.73 by July 01, 2026, with a range of $297.85 to $313.72. 1-Year Outlook: Projected gain of 7.79%, with price at $261.98 by April 02, 2027, within a range of $255.43 to $268.77.

Key Takeaways

Johnson & Johnson (NYSE:JNJ) shares are flat 5.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Johnson & Johnson trading at a premium to the broader market with a P/E of 22.02. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $190.95, suggesting -21.43% downside. Our AI forecast model points to short-term strength (5.63% over two weeks), a medium-term rise (25.38% over three months), and a longer-term gain (7.79% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Johnson & Johnson (JNJ) stock price?

Johnson & Johnson (NYSE: JNJ) stock price is $243.04 in the last trading session. During the trading session, JNJ stock reached the peak price of $247.21 while $242.00 was the lowest point it dropped to. The percentage change in JNJ stock occurred in the recent session was -0.44% while the dollar amount for the price change in JNJ stock was - $1.08.

JNJ's industry and sector of operation?

The NYSE listed JNJ is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Johnson & Johnson designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of JNJ?

Mr. Robert J. Decker Jr.
Controller & Chief Accounting Officer
Dr. Peter M. Fasolo Ph.D.
Executive Vice President & Chief HR Officer
Ms. Elizabeth Forminard
Executive Vice President & Gen. Counsel
Mr. Alex Gorsky
Executive Chairman
Dr. Guy J. Lebeau M.D.
Group Chairman of MD&D Bus. - EMEA
Mr. Joseph J. Wolk C.P.A.
Executive Vice President & Chief Financial Officer
Ms. Ashley A. McEvoy
Executive Vice President & Worldwide Chairman of MedTech
Mr. Thibaut Mongon
Chief Executive Officer & Director
Ms. Jennifer L. Taubert
Executive Vice President & Worldwide Chairman of Pharmaceuticals
Dr. John C. Reed M.D., Ph.D.
Executive Vice President of Pharmaceuticals R&D
Mr. Joseph J. Wolk CPA
Executive Vice President & Chief Financial Officer
Mr. Dirk Brinckman
Chief Compliance Officer
Mr. Joaquin Duato
Chief Executive Officer & Director
Mr. James Swanson
Executive Vice President & Chief Information Officer
Ms. Jessica Moore
Vice President of Investor Relations

How JNJ did perform over past 52-week?

JNJ's closing price is 71.76% higher than its 52-week low of $141.50 where as its distance from 52-week high of $251.71 is -3.44%.

How many employees does JNJ have?

Number of JNJ employees currently stands at 138,100.

Link for JNJ official website?

Official Website of JNJ is: https://www.jnj.com

How do I contact JNJ?

JNJ could be contacted at phone 732 524 0400 and can also be accessed through its website. JNJ operates from One Johnson & Johnson Plaza, New Brunswick, NJ 08933, United States.

How many shares of JNJ are traded daily?

JNJ stock volume for the day was 5.28M shares. The average number of JNJ shares traded daily for last 3 months was 8.87M.

What is the market cap of JNJ currently?

The market value of JNJ currently stands at $585.70B with its latest stock price at $243.04 and 2.41B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	138100
Beta	0.33
Sales or Revenue	$85.15B
5Y Sales Change%	0.097%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

JNJ Company Profile and Key Details

Johnson & Johnson

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways